FY2025 Earnings Estimate for Erasca Issued By HC Wainwright

Erasca, Inc. (NASDAQ:ERAS) – Stock analysts at HC Wainwright lifted their FY2025 earnings estimates for Erasca in a research report issued on Thursday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.44) for the year, up from their previous forecast of ($0.48). The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca’s Q4 2025 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.26) EPS.

A number of other brokerages have also recently commented on ERAS. Morgan Stanley reissued an “equal weight” rating and issued a $2.00 price target (down from $4.00) on shares of Erasca in a research report on Monday, August 18th. Wall Street Zen raised shares of Erasca from a “sell” rating to a “hold” rating in a research report on Sunday, September 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a report on Wednesday, October 8th. Stifel Nicolaus set a $6.00 price objective on shares of Erasca in a report on Thursday, November 6th. Finally, Bank of America reissued an “underperform” rating and issued a $1.00 target price (down previously from $4.00) on shares of Erasca in a report on Wednesday, September 3rd. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Erasca currently has a consensus rating of “Hold” and an average price target of $4.25.

Erasca Trading Up 1.6%

Shares of ERAS stock opened at $2.58 on Monday. The company’s fifty day moving average price is $2.18 and its 200-day moving average price is $1.71. The stock has a market cap of $731.97 million, a PE ratio of -5.73 and a beta of 1.19. Erasca has a 12 month low of $1.01 and a 12 month high of $3.30.

Erasca (NASDAQ:ERAS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11).

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets increased its stake in shares of Erasca by 58.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock valued at $27,000 after purchasing an additional 7,923 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Erasca in the 2nd quarter worth approximately $29,000. Russell Investments Group Ltd. acquired a new position in Erasca in the 3rd quarter valued at about $31,000. SG Americas Securities LLC purchased a new stake in shares of Erasca during the third quarter worth $32,000. Finally, Crowley Wealth Management Inc. acquired a new stake in Erasca in the third quarter valued at approximately $33,000. 67.78% of the stock is owned by institutional investors and hedge funds.

About Erasca

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.